Relmada Therapeutics, Inc.

Ladies and gentlemen, and welcome to the RealMata Therapeutics Inc. Second Quarter 2022 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Brian Ritchie of LifeSite Advisor. Please go ahead, sir.

Thank you, Operator, and thank you all for joining us this afternoon. With me on today's call are Chief Executive Officer Sergio Traversa, Don Hickson, Head of Commercial, and Chief Financial Officer, Maggot Shenouda. This afternoon, ROMADA issued a news release providing a business update announcing financial results for the three and six months ended June 30th, 2022, and filed its quarterly report on Form 10-Q with the SEC. Please note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that during this call, LaMotta's management team will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in LaMotta's press release issued today and the company's SEC filings, including in the annual report on Form 10-K for the year ended December 31st, 2021, and subsequent filings. This conference call also contains time-sensitive information that is accurate only as of the date of this live broadcast, August 11, 2022. Ramada undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call. Now, I'd like to turn the call over to Sergio. Please go ahead, Sergio.

Thank you, Brian, as always. And good afternoon to everyone. I'm pleased to welcome you to the Relmada Second Quarter 2022 Conference Call. During today's call, I will review our recently achieved milestones and provide an update on the anticipated timeline associated with the multiple expected clinical trial readouts from REL 1017. Our lead product candidate that we are currently studying is a paradigm-shifting novel treatment for patients with major depressive disorder, or MDD. Following my comments, Magat Shenouda, our chief financial officer, will review our financial results and balance sheet, and we will then take your questions. We are approaching multiple key catalysts from our ongoing late-stage Reliance clinical development program. Specifically, we anticipate completing the enrollment of Reliance III the ongoing monotherapy registration on phase three trial shortly. More specifically, we expect to enroll the last patient in this trial before the end of August, probably earlier than that. This will be followed soon thereafter by a top-line readout of the study in the second half of this year. We also continue to expect top-line results from reliance one and reliance two in the second half of 2022. As a reminder, RELAS-1 and RELAS-2 are two ongoing Phase III sister two-arm placebo-controlled pivotal studies evaluating REL-1017-25mg as a potential adjunctive treatment for MDD. RELAS-3 is the ongoing Phase III two-arm placebo-controlled registrational study evaluating REL-1017-25mg as a potential monotherapy single-agent treatment for MDD. All participants in all of the Reliance trials take a loading dose on day one of 75 milligrams, three tablets, or REL-1017. We are also delighted to share that the FDA very recently granted fast-track designation to REL-1017 as a monotherapy single agent for the treatment of major depressive disorders. Our commercial preparations as have also continued with an expansion of our senior management team. Most recently, we are thrilled to welcome John Hickson to RealMada's head of commercial. John has over 36 years of sales and marketing experience within the biopharmaceutical industry, including a 31-year career with Eli Lilly and company. John is on the call, so before I go further, John, would you like to say a few words? Is it your first Conference call. We'd remind you to just join, and I'd be happy if you can say a few words.